<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Neonatal <z:mp ids='MP_0005039'>hypoxia</z:mp>-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (HI) is an important clinical problem with few effective treatments </plain></SENT>
<SENT sid="1" pm="."><plain>Granulocyte-colony stimulating factor (G-CSF) is an endogenous <z:chebi fb="0" ids="25905">peptide hormone</z:chebi> of the hematopoietic system that has been shown to be neuroprotective in focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in vivo and is currently in phase I/II clinical trials for <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in humans </plain></SENT>
<SENT sid="2" pm="."><plain>We tested G-CSF in a rat model of neonatal <z:mp ids='MP_0005039'>hypoxia</z:mp>-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in postnatal day 7 unsexed rat pups </plain></SENT>
<SENT sid="3" pm="."><plain>Three groups of animals were used: <z:mp ids='MP_0005039'>hypoxia</z:mp>-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (HI, n=67), <z:mp ids='MP_0005039'>hypoxia</z:mp>-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> with G-CSF treatment (HI+G, n=65), and healthy control (C, n=53) </plain></SENT>
<SENT sid="4" pm="."><plain>G-CSF (50 microg/kg, subcutaneous) was administered 1 h after HI and given on four subsequent days (five total injections) </plain></SENT>
<SENT sid="5" pm="."><plain>Animals were euthanized 24 h, 1, 2, and 3 weeks after HI </plain></SENT>
<SENT sid="6" pm="."><plain>Assessment included brain weight, histology, immunohistochemistry, and Western blotting </plain></SENT>
<SENT sid="7" pm="."><plain>G-CSF treatment was associated with improved quantitative brain weight and qualitative Nissl histology after <z:mp ids='MP_0005039'>hypoxia</z:mp>-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>TUNEL demonstrated <z:mp ids='MP_0006043'>reduced apoptosis</z:mp> in group HI+G </plain></SENT>
<SENT sid="9" pm="."><plain>Western blot demonstrated decreased expression of Bax and cleaved caspase-3 in group HI+G </plain></SENT>
<SENT sid="10" pm="."><plain>G-CSF treatment was also associated with increased expression of STAT3, Bcl-2, and Pim-1, <z:hpo ids='HP_0000001'>all</z:hpo> of which may have participated in the anti-apoptotic effect of the drug </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude that G-CSF ameliorates <z:e sem="disease" ids="C0752304" disease_type="Disease or Syndrome" abbrv="">hypoxic-ischemic brain injury</z:e> and that this may occur in part by an inhibition of apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
</text></document>